Tubulis Technologies
The company develops antibody-drug conjugates (ADCs) with specific biophysical properties designed for durable on-tumor delivery and anti-tumor activity. Its clinical pipeline includes candidates TUB-040 and TUB-030, which target solid tumor indications such as platinum-resistant ovarian cancer. The firm was recently acquired by Gilead Sciences to integrate its ADC technology suite into a broader oncology portfolio.
Biotechnology
Oncology
Pharmaceuticals
Healthtech
Funding summary
- Total raised
- €378.7M
- Funding rounds
- 3
Investors in Tubulis Technologies
Investors on record for Tubulis Technologies. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Tubulis Technologies?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors